N-(3-methoxyphenyl)-1H-benzimidazol-2-amine | 630092-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-(3-methoxyphenyl)-1H-benzimidazol-2-amine
• CAS: 630092-22-7
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: OCYPNZCYZZWQME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氯-2-甲硫基嘧啶-5-羧酸乙酯 、 N-(3-methoxyphenyl)-1H-benzimidazol-2-amine 在 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 72.0h， 生成 9-(3-Methoxyphenyl)-4-methylsulfanyl-1,3,5,9,11-pentazatetracyclo[8.7.0.02,7.012,17]heptadeca-2,4,6,10,12,14,16-heptaen-8-one
  参考文献：
  名称：

  Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity

  摘要：

  Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological, characterization of 2-amino-6phenylpyrirnido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5',4':5,6]pyrimido-[1,2-a]benzimidazol-5(6H)-one (25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.

  DOI：

  10.1021/jm701095m
• 作为产物：
  描述：

  在 C₁₅H₁₂N₄O₃ 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 8.0h， 以93%的产率得到N-(3-methoxyphenyl)-1H-benzimidazol-2-amine
  参考文献：
  名称：

  从头设计和合成双吡啶并嘌呤酮衍生物作为生产性鸟苷化反应中的可见光光催化剂

  摘要：

  本文描述了一系列 6 H-联吡啶并[1,2- e :2',1'- i ]purin-6-ones (DPs) 作为新型可见光光氧化还原催化剂的从头设计和合成（件）。合成的DP1-5的λ Abs(max)值分别在 433-477 nm，激发态氧化还原电位分别在 1.15-0.69 eV 和 -1.41 到 -1.77 eV（相对于SCE）。作为代表，DP4能够对各种胺进行有效的鸟苷化，包括 1°、2° 和 3°-烷基伯胺、仲胺、芳基和杂芳基胺、氨基腈、氨基酸和肽以及丙炔胺和 α-氨基酯，从而产生多样性在生物学上重要的胍和环状胍中。DP4在鸟苷酸化反应中的光催化功效超过了常用的 Ir 和 Ru 多吡啶基配合物，以及一些有机 PC。该方法的其他显着优点包括广泛的底物范围和官能团耐受性、克级合成和通用的后期衍生化，导致衍生物81对具有 IC 50的拉莫斯细胞表现出 60 倍更好的抗癌活性 比临床药物依鲁替尼

  DOI：

  10.1039/d1sc05294b

文献信息

• An efficient method to access 2-substituted benzimidazoles under solvent-free conditions
  作者：Ping Lan、F. Anthony Romero、Threshia S. Malcolm、Benjamin D. Stevens、Dariusz Wodka、Gergely M. Makara

  DOI：10.1016/j.tetlet.2008.01.100

  日期：2008.3

  An expeditious method to access 2-substituted benzimidazoles was developed. Both aromatic (phenols, anilines, and thiophenols) and alkyl nucleophiles (amines and thiols) react with 2-methylsulfonyl benzimidazole under solvent-free conditions to generate a variety of 2-substituted benzimidazoles. (c) 2008 Elsevier Ltd. All rights reserved.
• Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-<i>a</i>]benzimidazol-5(6<i>H</i>)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity
  作者：Matthew W. Martin、John Newcomb、Joseph J. Nunes、Christina Boucher、Lilly Chai、Linda F. Epstein、Theodore Faust、Sylvia Flores、Paul Gallant、Anu Gore、Yan Gu、Faye Hsieh、Xin Huang、Joseph L. Kim、Scot Middleton、Kurt Morgenstern、Antonio Oliveira-dos-Santos、Vinod F. Patel、David Powers、Paul Rose、Yanyan Tudor、Susan M. Turci、Andrew A. Welcher、Debra Zack、Huilin Zhao、Li Zhu、Xiaotian Zhu、Chiara Ghiron、Monika Ermann、David Johnston、Carl-Gustaf Pierre Saluste

  DOI：10.1021/jm701095m

  日期：2008.3.1

  Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological, characterization of 2-amino-6phenylpyrirnido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5',4':5,6]pyrimido-[1,2-a]benzimidazol-5(6H)-one (25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.
• <i>De novo</i> design and synthesis of dipyridopurinone derivatives as visible-light photocatalysts in productive guanylation reactions
  作者：Yameng Wan、Hao Wu、Nana Ma、Jie Zhao、Zhiguo Zhang、Wenjing Gao、Guisheng Zhang

  DOI：10.1039/d1sc05294b

  日期：——

  Described here is the de novo design and synthesis of a series of 6H-dipyrido[1,2-e:2′,1′-i]purin-6-ones (DPs) as a new class of visible-light photoredox catalysts (PCs). The synthesized DP1–5 showed their λAbs(max) values in 433–477 nm, excited state redox potentials in 1.15–0.69 eV and −1.41 to −1.77 eV (vs. SCE), respectively. As a representative, DP4 enables the productive guanylation of various

  本文描述了一系列 6 H-联吡啶并[1,2- e :2',1'- i ]purin-6-ones (DPs) 作为新型可见光光氧化还原催化剂的从头设计和合成（件）。合成的DP1-5的λ Abs(max)值分别在 433-477 nm，激发态氧化还原电位分别在 1.15-0.69 eV 和 -1.41 到 -1.77 eV（相对于SCE）。作为代表，DP4能够对各种胺进行有效的鸟苷化，包括 1°、2° 和 3°-烷基伯胺、仲胺、芳基和杂芳基胺、氨基腈、氨基酸和肽以及丙炔胺和 α-氨基酯，从而产生多样性在生物学上重要的胍和环状胍中。DP4在鸟苷酸化反应中的光催化功效超过了常用的 Ir 和 Ru 多吡啶基配合物，以及一些有机 PC。该方法的其他显着优点包括广泛的底物范围和官能团耐受性、克级合成和通用的后期衍生化，导致衍生物81对具有 IC 50的拉莫斯细胞表现出 60 倍更好的抗癌活性 比临床药物依鲁替尼